LifeSci Capital initiated coverage of Aquestive Therapeutics (AQST) with an Outperform rating and $10 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Optimistic Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s Market Potential and Strategic Leadership
- Aquestive Therapeutics’ Earnings Call: Progress Amid Challenges
- Aquestive Therapeutics: Advancing Anaphylm and Strategic Preparations Support Buy Rating
- Aquestive Therapeutics Announces $85M Stock Offering
- Aquestive Therapeutics 21.25M share Secondary priced at $4.00